Rephonic
Artwork for Decera Clinical Education Oncology Podcast

Decera Clinical Education Oncology Podcast

Decera Clinical Education
Non-Small Cell Lung Cancer
BTK Inhibitors
Chronic Lymphocytic Leukemia
Multiple Myeloma
CAR T-Cell Therapy
Clinical Trials
Bispecific Antibodies
Biomarker Testing
Breast Cancer
Ovarian Cancer
Immunotherapy
Her2-Positive Metastatic Breast Cancer
CDK4/6 Inhibitors
ROS1
Polycythemia Vera
Essential Thrombocythemia
Mantle Cell Lymphoma
Venetoclax
Endometrial Cancer
NCCN Guidelines

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

PublishesTwice weeklyEpisodes257Founded6 years ago
Number of ListenersCategories
Health & FitnessEducationCoursesMedicine

Listen to this Podcast

Artwork for Decera Clinical Education Oncology Podcast

Latest Episodes

In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including:

• Contemporary Risk Stratification

... more

YouTube

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as ... more

YouTube

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including:

• The incidence of cytokine release syndrome ... more

YouTube

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including:

• The evolving role of chemotherapy

• Utility of tumor treating fields for the treatment of locally advanced pancr... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Thomas Bachelot
Medical oncologist
Léon Bérard Center, Lyon, France
Episode: Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC
Mafalda Oliveira
Oncologist
Vall d'Hebron University Hospital, Barcelona, Spain
Episode: Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC
Paul Oberstein
GI Medical Oncologist, Associate Professor of Medicine, NYU Langone Health
New York University Langone Health
Episode: Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
Andrew Ko
GI Medical Oncologist, Professor of Medicine
University of California, San Francisco
Episode: Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
Efrat Dotan
GI Medical Oncologist, Professor of Medicine
University of Pennsylvania
Episode: Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
Dr. Jesus Berdeja
Oncologist
Tennessee Oncology, Nashville
Episode: Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Dr. Amrita Krishnan
Oncologist
City of Hope, Irvine, California
Episode: Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Dr. Donald Moore
Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Episode: What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
Dr. Anthony Perissinotti
Hematology Clinical Pharmacist Specialist
University of Michigan
Episode: What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma

Hosts

Gervais Constanze
Host of the Decera Clinical Education Oncology Podcast
Sharif Mursalib
Host of Decera Clinical Education Oncology Podcast

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#139
Australia/Education/Courses
Apple Podcasts
#43
India/Education/Courses
Apple Podcasts
#53
Sweden/Education/Courses
Apple Podcasts
#60
Saudi Arabia/Education/Courses
Apple Podcasts
#62
Japan/Education/Courses
Apple Podcasts
#74
Israel/Education/Courses
Apple Podcasts
#89
Argentina/Education/Courses
Apple Podcasts
#106
New Zealand/Education/Courses
Apple Podcasts
#121
Denmark/Education/Courses
Apple Podcasts
#133
Austria/Education/Courses
Apple Podcasts
#142
Taiwan/Education/Courses
Apple Podcasts
#214
South Korea/Education/Courses

Talking Points

Recent interactions between the hosts and their guests.

What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
Q: How are centers deciding between bispecific antibodies, CAR T cells, and ADCs for patients in the early relapse setting?
Centers assess access to CAR T programs, patient suitability and disease burden, logistical capabilities for inpatient versus outpatient care, and the relative toxicity profiles. The goal often involves bridging to CAR T when possible, using bispecific antibodies for disease control and outpatient management, and reserving ADCs like belantamab mafodotin for appropriate cases while managing ocular toxicity risks.
Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Q: Where should GPRC5D therapies fit in the treatment sequence relative to BCMA therapies?
Experts view GPRC5D therapies as potentially useful after BCMA, with some data suggesting post-BCMA activity, but there is active discussion about optimal placement, including earlier lines in certain combinations, and the consensus is that sequencing choices will depend on patient-specific factors and evolving trial data.
Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Q: How did Talquetamab get approved and what populations were studied?
Talquetamab gained approval based on Monumental 1 data showing activity in patients with relapsed/refractory myeloma who had prior BCMA-directed therapy, including those who had received T cell redirecting therapies, indicating meaningful response rates and tolerable safety when used in appropriate settings.
Global Experts Discuss Current and Emerging Treatments for ET and PV
Q: How are newer therapies changing the ET/PV landscape, and is there evidence of disease modification?
Second-line agents like oxalitinib and long-acting pegylated interferons show improvements in hematocrit control and symptom burden, and early data suggest possible disease-modifying effects with decreased mutant allele burden in some patients, indicating a shift beyond symptom control toward altering disease biology.
Global Experts Discuss Current and Emerging Treatments for ET and PV
Q: What are the current foundational targets and strategies for PV management?
A hematocrit target of 45% or less, achieved through phlebotomy and often combined with low-dose aspirin, remains central to PV management to reduce thrombosis risk, with stratification into low- and high-risk groups guiding treatment intensity.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

This show centers on practical oncology and hematology guidance, featuring clinicians, researchers, pharmacists, and patient advocates who dissect current and emerging therapies, diagnostic strategies, and real-world care pathways. Episodes frequently explore biomarker-driven treatment decisions, sequencing of therapies, management of toxicities, and how new data translates into frontline and advanced-stage care. A recurring strength is the blend of academic expertise from major centers with real-world perspectives on outpatient administration, access to therapies, and multidisciplinary care, often framed by practical case discussions and healthcare system considerations. The format tends to emphasize actionable insights for clinicians, APP... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. Two Onc Docs
2. OncLive® On Air
3. Oncology Today with Dr Neil Love
4. Oncology Brothers: Practice-Changing Cancer Discussions
5. Research To Practice | Oncology Videos

How many episodes of this podcast are there?

this podcast launched 6 years ago and published 257 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Thomas Bachelot
2. Mafalda Oliveira
3. Paul Oberstein
4. Andrew Ko
5. Efrat Dotan
6. Dr. Jesus Berdeja
7. Dr. Amrita Krishnan
8. Dr. Donald Moore

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days